Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04958811
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
- NCT04958811 ↗
- Active, not recruiting
- Georgetown University
- Focused
We haven't built an HCP commentary report on NCT04958811 (tiragolumab plus atezolizumab plus bevacizumab in previously-treated advanced non-squamous NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04958811 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Non-squamous Non-small-cell Lung Cancer
- Interventions
- Tiragolumab; Atezolizumab; Bevacizumab
- Arms
- Tiragolumab plus atezolizumab and bevacizumab · Experimental
- Enrollment
- 29
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Georgetown University with Genentech, Inc.
- Start
- Dec 21, 2021
- Primary completion
- Nov 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04958811 · updated Sep 10, 2026